FDA to review Mitsubishi’s ALS drug
US regulators have agreed to review Mitsubishi Tanabe’s application to market edaravone for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease.
Read More
Tag: Mitsubishi Tanabe
FDA to review Mitsubishi’s ALS drug
US regulators have agreed to review Mitsubishi Tanabe’s application to market edaravone for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
